On March 24, 2026, Karyopharm Therapeutics Inc. (the "Company") entered into a Securities Purchase Agreement with RA Capital Management (the "Investor"). Under this agreement, the Company agreed to issue and sell 1,030,354 shares of its common stock at a purchase price of $6.785 per share, along with pre-funded warrants to purchase up to 3,391,164 shares of common stock at a price of $6.7849 per warrant. Additionally, the Company will issue accompanying warrants to purchase 4,421,518 shares of common stock with an exercise price of $10.00 per share. The private placement closed on March 26, 2026, resulting in gross proceeds of approximately $30 million before placement agent fees and offering expenses. Furthermore, in March 2026, the Company issued and sold an aggregate of 2,994,441 shares of common stock under its Open Market Sale Agreement with Jefferies LLC, generating total proceeds of approximately $19.8 million. This amount includes the 1,100,844 shares previously disclosed in the Company’s Current Report on Form 8-K filed on March 24, 2026. Following these transactions, the Company will have 22,543,316 shares of common stock outstanding and pre-funded warrants to purchase an aggregate of 4,005,556 shares of common stock. The Company anticipates that its existing liquidity, including cash, cash equivalents, and investments, along with cash flow from net product revenue and other revenue, will enable it to fund its current operating plans into late in the third quarter of 2026.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.